Patrik Roser, PhD, MD Biography
- Title:
- Professor of Psychiatry at Ruhr-University Bochum (Germany)
- Position:
- Con to the question "Should Marijuana Be a Medical Option?"
- Reasoning:
-
“Reduced amplitudes of auditory evoked P300 are a robust finding in schizophrenic patients, indicating deficient attentional resource allocation and active working memory. Delta9-Tetrahydrocannabinol (Delta9-THC), the main active constituent of Cannabis sativa, has been known to acutely impair cognitive abilities in several domains, particularly in memory and attention. Given the psychotic-like effects of Delta9-THC, a cannabinoid hypothesis of schizophrenia has been proposed. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on P300 amplitude in 20 healthy volunteers (age 28.2+/-3.1 years, 10 male) by comparing Delta9-THC and standardized cannabis extract containing Delta9-THC and cannabidiol (CBD)… CBD has been known to abolish many of the psychotropic effects of Delta9-THC, but, unexpectedly, failed to demonstrate a reversal of Delta9-THC-induced P300 reduction… These data suggest that Delta(9)-THC may lead to acute impairment of attentional functioning and working memory.”
“Effects of Acute Oral Delta9-tetrahydrocannabinol and Standardized Cannabis Extract on the Auditory P300 Event-related Potential in Healthy Volunteers,” European Neuropsychopharmacology, Aug. 2008
- Involvement and Affiliations:
-
- Professor, Department of Psychiatry, LWL University Hospital, Ruhr-University Bochum (Germany)
- Professor, Department of Psychiatry and Psychotherapy, Charité University Hospital Berlin (Germany)
- Research Group, Clinical and Experimental Psychopathology, Department of General and Social Psychiatry, Psychiatric University Hospital Zurich (Switzerland)
- Education:
-
- PhD, school and date unknown
- MD, school and date unknown
- Other:
-
- None found